Dr. Kevin Haas
Equibles does not estimate personal net worth.
Get an email with a short summary when Veracyte, Inc. publishes a filing, an earnings call transcript or a press release.
Get VCYT alertsAbout Dr. Kevin Haas
Dr. Kevin Haas is recorded as CTO at Veracyte, Inc. (VCYT) since March 24, 2026. Veracyte, Inc. reported in an 8-K filed March 16, 2026 that Dr. Kevin Haas was appointed Chief Development and Technology Officer, effective March 24, 2026. Veracyte, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Veracyte, Inc. includes Marc Stapley (CEO and Board Member), Bonnie H. Anderson (Chairman), Rebecca Chambers (CFO) and 7 others.
“On March 16, 2026, Veracyte, Inc. (the "Company") announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026.”
Affiliation history
-
Veracyte, Inc. (VCYT)
SEC 8-K
Current2026-03-24–present
-
Current
2026-03-24–present
Company network
Leadership on record at Veracyte, Inc.
- Marc Stapley CEO, Board Member
- Bonnie H. Anderson Chairman
- Rebecca Chambers CFO
- Christopher Hall COO
- Annie McGuire General Counsel
- Beverly Jane Alley Chief Accounting Officer
- Jonathan Wygant Chief Accounting Officer
- Brent Shafer Board Member
- Eliav Barr, M.D. Board Member
- Tom Miller Board Member